Related Panel outlines efforts to find COVID-19 cure, including phase 3 trials at BWH Single-shot COVID-19 vaccine proves successful with primates Some human testing begun, with phase 3 trials possible as soon as September Most people with COVID-19 have relatively mild disease, but a subset of them develop severe pneumonia and respiratory failure, potentially leading to death. In new research published today in Nature Medicine, immunologist Dan H. Barouch and colleagues at Harvard-affiliated Beth Israel Deaconess Medical Center (BIDMC) demonstrated that the optimal vaccine elicited robust immune response in Syrian golden hamsters and prevented severe clinical disease — including weight loss, pneumonia, and death. In recently published previous work, Barouch, the William Bosworth Castle Professor of Medicine at Harvard Medical School, and his colleagues showed that a candidate COVID-19 vaccine raised neutralizing antibodies that robustly protected non-human primates (NHPs) against SARS-CoV-2, the virus that causes COVID-19. “We recently reported that an Ad26-based SARS-CoV-2 vaccine provided robust protection in rhesus macaques, and this vaccine is currently being evaluated in humans,” said Barouch, who is director of BIDMC’s Center for Virology and Vaccine Research. “However, nonhuman primates typically don’t get severe clinical disease, and thus it was important to study whether this vaccine could prevent severe pneumonia and death due to SARS-CoV-2 in hamsters, which are more susceptible to clinical disease.”,The vaccine — developed through a collaboration between BIDMC and Johnson & Johnson (J&J) — uses a common cold virus, called adenovirus serotype 26 (Ad26), to deliver the SARS-CoV-2 spike protein into host cells, where it stimulates the body to raise immune responses against the coronavirus. Barouch’s group and J&J developed a series of vaccine candidates designed to express different variants of the SARS-CoV-2 spike protein, which is the major target for neutralizing antibodies. In the current study, the researchers immunized Syrian golden hamsters with a single injection of the Ad26-based SARS-CoV-2 vaccine, which induced neutralizing antibodies in all animals. Four weeks later, the animals were exposed to a high dose of SARS-CoV-2. Vaccinated animals lost less weight and had less virus in their lungs and other organs than unvaccinated control animals. Vaccinated animals also demonstrated lower mortality. Moreover, the researchers found that neutralizing antibody responses were inversely correlated with weight loss and viral loads in respiratory tissues. The Ad26.COV2.S vaccine is currently being evaluated in clinical studies to establish the performance of the vaccine candidate in humans.“This hamster model of severe COVID-19 disease should prove useful to complement current nonhuman primate models in the evaluation of candidate vaccines and therapeutics,” said Barouch, who is also the William Bosworth Castle Professor of Medicine at Harvard Medical School, a member of the Ragon Institute of MGH, MIT, and Harvard, and the co-leader of the vaccine working group of the Massachusetts Consortium on Pathogen Readiness. In July 2020, investigators at BIDMC and other institutions initiated a first-in-human Phase 1/2 clinical trial of the Ad26.COV2.S vaccine in healthy volunteers. Kathryn E. Stephenson is the principal investigator for the trial at BIDMC, which is funded by Janssen Vaccines & Prevention, B.V., a pharmaceutical research arm of Johnson & Johnson. Pending clinical trial outcomes, the Ad26.COV2.S vaccine is on track to start a phase 3 efficacy trial in up to 60,000 participants this month. Global race to a COVID-19 vaccine Vaccines may arrive in record time, but the virus has been faster The Daily Gazette Sign up for daily emails to get the latest Harvard news. Team at Harvard plans to launch clinical trial in fall
Tag: 夜上海论坛FO Ag Dept denies egg farm permit
State Agriculture officials announced October 1, 2002, that they have denied the application by Vermont Egg Farm (VEF) for a proposed expansion that would have more than doubled the size of its Highgate facility. In an 8-page finding, the Department cited a number of concerns in denying the expansion, primarily centering on manure management and its direct relationship to the potential return of the fly problem that plagued the facility in its early years of operation. “I considered this decision very carefully,” said Agriculture Commissioner Leon Graves, “because a big part of my job is to encourage and support all of the diversified agricultural interests of Vermont including small, medium, large and expanding farming operations. In the end, however, Vermont Egg Farm simply failed to meet the requirements for adequate manure management as called for by the LFO (Large Farm Operation) law.” The expansion application has generated a great deal of controversy since being deemed complete the first time in February of 2002. Just over one month later, the application was rendered incomplete due to revisions of the manure management plan. After more than five months passed, an amended manure management plan was resubmitted to the Department of Agriculture by Vermont Egg Farm. The application was recently deemed complete again on September 10. In both cases, a 10-day public comment period was offered. Graves, who operated a small dairy farm in Fairfield for many years prior to being named Commissioner of Agriculture, said public input is a crucial part of the process. However, Graves said that for the LFO process to have legitimacy it can’t be subject to political concerns or popular opinion and each application must be judged on its merits on a case-by-case basis. “It is the public policy of this state as expressed in law, and my own personal belief as well, that diverse agricultural operations are essential to our rural communities and character, that farming preserves the environmental resources of the state, that farming furthers the economic self-sufficiency of the state, and that agriculture provides a general benefit to the health and welfare of the people of the state,” Graves said. “These policies do not equate this value to the relative size of an agricultural operation, however,” said Graves, “and it is for this very reason we have the LFO law in Vermont. To remain economically viable some farms may choose to expand and we have to allow them this option. At the same time, we have to make sure that this is done in an agriculturally sound way.” “We have been hearing about the increase of large farms inVermont. The truth is that only 17 farms in Vermont — just slightly over 1.1 percent of our approximately 1,500 dairy farms and less than 2/10 of one percent of our 6,700 total farms — are permitted as large farms.” “Furthermore,” Graves added, “all but one of our large farms are family owned and support not only the families that run them but as many as 20 other individuals and their families, not to mention the tax base of their communities and the businesses that supply them.” Graves encouraged anyone with questions about large farms and the LFO permit process to contact the Department of Agriculture in Montpelier.
Tag: 夜上海论坛FO Vattenfall Delays Danish Duo
Vattenfall has delayed the construction of the Vesterhav Syd and Vesterhav Nord offshore wind projects in Denmark by three years.According to turbine supplier Siemens Gamesa, the beginning of installation has been postponed to 2023, instead of 2020 as originally agreed.The Danish Energy Agency recently initiated new environmental impact assessment (EIA) processes for both Vesterhav Syd and Vesterhav Nord.An EIA supplement will now be drawn up, after which the agency will be able to make its final decision.To remind, Vattenfall made an official turbine order with Siemens Gamesa in May last year for the supply, service and maintenance of a total of circa 350MW for the two projects.The Vesterhav Syd and Vesterhav Nord offshore wind farms will comprise a total of 41 8MW turbines located off the west coast of Jutland.